broad applications discovery, page-12

Some more from Celera's 2010 Form 10 K

"Our proteomics research is currently focused primarily on diagnostic applications such as the identification of proteins in blood of individuals with lung cancer and their use in a potential confirmatory diagnostic test for distinguishing benign from malignant nodules previously detected by a low dose computerized tomography (LDCT) scan as well as their use in a potential screening test to identify high risk individuals who may benefit from a LDCT scan. Having completed the marker discovery aspect of our proteomics program in cancer at the end of 2009, we transferred the diagnostic lung cancer program initiated in our Rockville, MD facility to our Alameda facility for further development."

http://www.faqs.org/sec-filings/100310/Celera-CORP_10-K/

It's all looking good IMHO.

Another extract from the Form 10 K on market competition. After Roche & Gen-Probe, Celera sits with similar market share to the next 4 buggest players:

"Our Products business competes with companies in the U.S. and abroad that are engaged in the development and commercialization of molecular diagnostic products. We believe that the market leader for these products is F. Hoffmann-La Roche, Ltd., followed by Gen-Probe Incorporated, and that Celera has approximately the same market share as the next four companies in this market Becton, Dickinson and Company, Qiagen N.V. (Qiagen), Cepheid and Siemens Medical Solutions Diagnostics."

IMHO this all means that the lung test kit development is indeed a KEY PRODUCT being developed by an INDUSTRY LEADER.

On timings, I can only go by the company suggestions of a 2012 release and note that the CDY licence was purchased around the same time that the discovery aspects of the proteomics program were completed. While there are no guarantees in this high risk game, the cards seem to be aligned from my own uninformed perspective.

cheers